Skip to content

Advertisement

Journal for ImmunoTherapy of Cancer

What do you think about BMC? Take part in

Reviews

Section edited by Thomas F. Gajewski, MD, PhD and Per Thor Straten, PhD

Fact/data-driven works that cumulate several articles of importance on a particular subject or research area in a review format with the goal of providing the “state of the art” in the field. Includes recent major advances and discoveries, significant gaps in the research, current debates, and/or ideas of where research might go next.

Previous Page Page 1 of 3 Next Page
  1. Content type: Review

    With the approval of talimogene laherparepvec (T-VEC) for inoperable locally advanced or metastatic malignant melanoma in the USA and Europe, oncolytic virotherapy is now emerging as a viable therapeutic optio...

    Authors: Adam Ajina and John Maher

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:90

    Published on:

  2. Content type: Review

    Treatment options for metastatic urothelial carcinoma (mUC) remained relative unchanged over the last 30 years with combination chemotherapy as the mainstay of treatment. Within the last year the landscape for...

    Authors: David H. Aggen and Charles G. Drake

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:94

    Published on:

  3. Content type: Review

    Metastatic disease is the leading cause of death among cancer patients and involves a complex and inefficient process. Every step of the metastatic process can be rate limiting and is influenced by non-maligna...

    Authors: Louise M.E. Janssen, Emma E. Ramsay, Craig D. Logsdon and Willem W. Overwijk

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:79

    Published on:

  4. Content type: Review

    The use of immunomodulation to treat malignancies has seen a recent explosion in interest. The therapeutic appeal of these treatments is far reaching, and many new applications continue to evolve. In particula...

    Authors: Ryan Slovak, Johannes M. Ludwig, Scott N. Gettinger, Roy S. Herbst and Hyun S. Kim

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:78

    Published on:

  5. Content type: Meeting report

    Understanding how murine models can elucidate the mechanisms underlying antitumor immune responses and advance immune-based drug development is essential to advancing the field of cancer immunotherapy. The Soc...

    Authors: Andrew Zloza, A. Karolina Palucka, Lisa M. Coussens, Philip J. Gotwals, Mark B. Headley, Elizabeth M. Jaffee, Amanda W. Lund, Arlene H. Sharpe, Mario Sznol, Derek A. Wainwright, Kwok-Kin Wong and Marcus W. Bosenberg

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:77

    Published on:

  6. Content type: Review

    Therapeutic efforts to engage the immune system against cancer have yielded exciting breakthroughs and a growing list of approved immune-based agents across a variety of disease states. Despite the early succe...

    Authors: James L. Gulley, Elizabeth A. Repasky, Laura S. Wood and Lisa H. Butterfield

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:55

    Published on:

  7. Content type: Review

    The tumor-permissive and immunosuppressive characteristics of tumor-associated macrophages (TAM) have fueled interest in therapeutically targeting these cells. In this context, the colony-stimulating factor 1 ...

    Authors: Michael A. Cannarile, Martin Weisser, Wolfgang Jacob, Anna-Maria Jegg, Carola H. Ries and Dominik Rüttinger

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:53

    Published on:

  8. Content type: Review

    This report is a summary of ‘New Cancer Immunotherapy Agents in Development’ program, which took place in association with the 31st Annual Meeting of the Society for Immunotherapy of Cancer (SITC), on November...

    Authors: Prasad S. Adusumilli, Edward Cha, Mark Cornfeld, Thomas Davis, Adi Diab, Thomas W. Dubensky Jr., Elizabeth Evans, Jane L. Grogan, Bryan A. Irving, Rom S. Leidner, Shane A. Olwill, Patrick Soon-Shiong, Frederic Triebel, David Tuck, Adrian Bot, Roger D. Dansey…

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:50

    Published on:

  9. Content type: Review

    As cancer strikes, individuals vary not only in terms of factors that contribute to its occurrence and development, but as importantly, in their capacity to respond to treatment. While exciting new therapeutic...

    Authors: Sacha Gnjatic, Vincenzo Bronte, Laura Rosa Brunet, Marcus O. Butler, Mary L. Disis, Jérôme Galon, Leif G. Hakansson, Brent A. Hanks, Vaios Karanikas, Samir N. Khleif, John M. Kirkwood, Lance D. Miller, Dolores J. Schendel, Isabelle Tanneau, Jon M. Wigginton and Lisa H. Butterfield

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:44

    Published on:

  10. Content type: Review

    Cancer immunotherapies are showing promising clinical results in a variety of malignancies. Monitoring the immune as well as the tumor response following these therapies has led to significant advancements in ...

    Authors: David F. Stroncek, Lisa H. Butterfield, Michael A. Cannarile, Madhav V. Dhodapkar, Tim F. Greten, Jean Charles Grivel, David R. Kaufman, Heidi H. Kong, Firouzeh Korangy, Peter P. Lee, Francesco Marincola, Sergio Rutella, Janet C. Siebert, Giorgio Trinchieri and Barbara Seliger

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:21

    Published on:

  11. Content type: Review

    Cancer immunotherapy and in particular monoclonal antibodies blocking the inhibitory programed cell death 1 pathway (PD-1/PD-L1) have made a significant impact on the treatment of cancer patients in recent yea...

    Authors: Patrick A. Ott, F. Stephen Hodi, Howard L. Kaufman, Jon M. Wigginton and Jedd D. Wolchok

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:16

    Published on:

  12. Content type: Review

    Established tumors build a stressful and hostile microenvironment that blocks the development of protective innate and adaptive immune responses. Different subsets of immunoregulatory myeloid populations, incl...

    Authors: Juan R. Cubillos-Ruiz, Eslam Mohamed and Paulo C. Rodriguez

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:5

    Published on:

  13. Content type: Review

    Despite recent major clinical breakthroughs in human cancer immunotherapy including the use of checkpoint inhibitors and engineered T cells, important challenges remain, including determining the sub-populatio...

    Authors: Jiwon S. Park, Sita S. Withers, Jaime F. Modiano, Michael S. Kent, Mingyi Chen, Jesus I. Luna, William T. N. Culp, Ellen E. Sparger, Robert B. Rebhun, Arta M. Monjazeb, William J. Murphy and Robert J. Canter

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:97

    Published on:

  14. Content type: Review

    Cancer therapies based on T cells have shown impressive clinical benefit. In particular, immune checkpoint blockade therapies with anti-CTLA-4 and anti-PD-1/PD-L1 are causing dramatic tumor shrinkage and prolo...

    Authors: Hiep Khong and Willem W. Overwijk

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:56

    Published on:

  15. Content type: Meeting report

    Treatment strategies that target the immune system provide the opportunity for antitumor activity across multiple cancer types, regardless of mutational status or tumor histology. While many of the initial adv...

    Authors: Paolo Antonio Ascierto, Giacomo Cartenì, Cesare Gridelli, Sandro Pignata, Antonio Pinto, Carmen Criscitiello, Luigi Buonaguro, Stefano Pepe, Roberto Mabilia, Vincenzo Montesarchio, Bruno Daniele and Sabino De Placido

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:41

    Published on:

Previous Page Page 1 of 3 Next Page

2016 Journal Metrics

  • Speed
    27 days from submission to first decision
    11 days from acceptance to publication

    Usage 
    358,247 downloads
    1157.0 Usage Factor

    Social Media Impact
    114 mentions

Advertisement